(Q42876160)

9 November 2017

title

Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option (English)

1 reference

9 November 2017

Kirstin Dienus

1

1 reference

9 November 2017

Ardeshir Bayat

series ordinal

2

1 reference

9 November 2017

Brendan F Gilmore

series ordinal

3

1 reference

9 November 2017

Oliver Seifert

series ordinal

4

1 reference

9 November 2017

publication date

26 September 2010

1 reference

Archives of Dermatological Research

9 November 2017

published in

1 reference

9 November 2017

volume

302

1 reference

9 November 2017

issue

10

1 reference

9 November 2017

page(s)

725-731

1 reference

Fibronectin is overproduced by keloid fibroblasts during abnormal wound healing

9 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Quality of life of patients with keloid and hypertrophic scarring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Levels of evidence for the treatment of keloid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Topical tamoxifen therapy in hypertrophic scars or keloids in burns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Promoted activation of matrix metalloproteinase (MMP)-2 in keloid fibroblasts and increased expression of MMP-2 in collagen bundle regions: implications for mechanisms of keloid progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Elevated vascular endothelial growth factor in keloids: relevance to tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Keloids--clinical diagnosis, pathogenesis, and treatment options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Gene expression profiling reveals alteration of caspase 6 and 14 transcripts in normal skin of keloid-prone patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Seprase: an overview of an important matrix serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Identification of unique gene expression patterns within different lesional sites of keloids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Keloid scarring: bench and bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Genetics of keloid scarring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

The influence of surgical excision margins on keloid prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

The molecular basis of keloid and hypertrophic scar formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Altered steady-state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Multiplexed particle-based flow cytometric assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-010-1084-X

10.1007/S00403-010-1084-X

21 January 2018

Identifiers

DOI

1 reference

9 November 2017

1 reference